ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing No Measurable Activity
ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors
Anti-amnesic and neuroprotective activities of ANAVEX 2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, in pharmacological and pathological models of amnesia.
